Writing in STAT last week, Julie Rehmeyer discussed the release of raw data from the PACE study, a clinical trial which has long been controversial amongst the very population it studied: people with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).
Rehmeyer, a CFS/ME patient herself, reports:
Under court order, the [PACE] study’s authors for the first time released their raw data earlier this month. Patients and independent scientists collaborated to analyze it and posted their findings Wednesday on Virology Blog, a site hosted by Columbia microbiology professor Vincent Racaniello. The analysis shows that if you’re already getting standard medical care, your chances of being helped by the treatments are, at best, 10 percent. And your chances of recovery? Nearly nil.
